← All trials
NCT05814835
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 7, 2022
- Primary completion
- Nov 30, 2023
- Completion date
- Dec 18, 2023
- First posted
- Apr 18, 2023
- Last posted
- Dec 20, 2023
- Enrollment
- 14
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- People's Liberation Army of ChinaOverall official - principal investigator
- People's Liberation Army of ChinaReponsible party - principal investigator
- Sinotau Pharmaceutical GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.